Comparative Efficacy and Safety of Biosimilar Bevacizumab (Stivant®) versus Reference Product (Avastin®) in Prethreshold Type I Retinopathy of Prematurity
{{output}}
Purpose: To compare the efficacy and safety of Stivant® (biosimilar bevacizumab, CinnaGen, Iran) to Avastin® (innovator bevacizumab, Genentech, South San Francisco, CA) in premature infants with prethreshold type I retinopathy ... ...
